about
Antibiotics for treating infected burn woundsCan we prevent antimicrobial resistance by using antimicrobials better?Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosisBacterial temporal dynamics enable optimal design of antibiotic treatmentMaintaining fluoroquinolone class efficacy: review of influencing factors.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.Measurement of tissue azithromycin levels in self-collected vaginal swabs post treatment using liquid chromatography and tandem mass spectrometry (LC-MS/MS).Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.Patients' interviews and misuse of antibiotics.Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.Antimicrobial therapy for bacillus anthracis-induced polymicrobial infection in (60)Co gamma-irradiated miceConcentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dosePharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic modelPharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionPharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia.Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media.Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.Single-dose azithromycin for respiratory tract infections.Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapyAntibiotic use in rural China: a cross-sectional survey of knowledge, attitudes and self-reported practices among caregivers in Shandong province.Protein binding of cefazolin is saturable in vivo both between and within patientsPostantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.Metrics for quantifying antimicrobial use in beef feedlotsPharmacokinetics of intraperitoneal gentamicin in peritoneal dialysis patients with peritonitis (GIPD study).Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosisPharmacokinetics and pharmacodynamics of antibacterial agents.In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models
P2860
Q24186213-AFD861EA-B165-4838-A42A-8960A7329325Q26829707-4B5E0658-57E8-4883-B475-AEDE1EA761A4Q28542435-E309AF08-16C0-4F35-B855-018E982A6BFFQ28546654-950FB3A3-AFF7-4714-8D00-886EAD52639BQ30310427-41A83C46-59BA-4205-A9D9-01FF568924A9Q33559139-1753F5A9-A7E7-4C6C-BE28-7F14D701B796Q33571422-7562E098-7F46-4D9D-8048-12D4C0DAEBE3Q33675064-A337ADF7-7955-457D-A8C8-AC7EB96010F7Q34058316-F448BA70-8DD3-4825-A530-41055599EB28Q34077069-C4492933-D845-4AD7-B96E-F60270A28E57Q34088337-88360952-C3B8-45D7-B556-BFFDCFB49B06Q34106577-8662DA86-F3D0-4611-97CB-6EC3C5F9041EQ34142444-005A3F89-E015-44D5-BA9A-968125D3C68BQ34230275-2D233355-5FD2-4A0A-853A-D0ABCD554E6EQ34230600-FFBEAEFC-F2F1-42B8-B629-B3D596B7CE36Q34301541-5DDB1091-DE33-4EC1-9429-77A0DA944524Q34307105-B5FE3995-B2DA-4ACA-877F-4AFAE1CF963BQ34483632-5BC7F992-6012-4452-9126-7A8E23F0D85BQ34820573-66EC2C96-12F5-44A1-AA3E-F373B6F575FFQ34937444-0332F8F4-3C9C-435A-ACCF-E143EF8F9F27Q35102656-BA4CCEEF-FF36-40A5-A3A3-12C074DCBC25Q35105913-4F4D7ED8-1F7C-4EFD-85F3-532ACA544F77Q35140423-80859F94-4257-4BF8-8DB4-5CB6ACF37113Q35168927-53A40D8A-3C5B-493E-84E8-DD3964481012Q35241405-502CCCC1-B8E5-422C-86F6-9A96799748D9Q35364184-2FBD9332-DAC9-4190-8F62-715F7DD33ACEQ35636012-21CCCD50-619B-46D9-A96F-9F20C2788B05Q35670035-AE4C067F-4F51-4538-8B27-F2AF205B257FQ35689377-4EC10997-23A1-4FEF-914C-F818788F84F0Q35874117-93F27F12-8877-4104-9188-85450E0B0202Q36024418-4FBACC2F-2858-423E-9743-39E230735DA4Q36048663-6090FB92-8D1C-44FB-8B05-8459E8F8FF52Q36099766-ACF6F4C7-0A85-491D-8619-BA5C9023E59DQ36126934-91D052A4-3B6E-482E-9F52-5E1AA989067CQ36162355-F1B9EDD0-DE4C-45F5-A40A-6F8CC9BAF848Q36325324-5675F667-6410-4E01-9991-FDBB54722B87Q36505518-D164D323-0C88-4773-8B3C-EE7A87AD07BAQ36669451-D57C692C-3697-40F8-8521-FC40F894012CQ36911111-109A964C-BF72-4693-AF87-3EF24E537721Q36932924-1A41582C-4DD0-428C-8983-13BF637E4BCA
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Does the dose matter?
@ast
Does the dose matter?
@en
Does the dose matter?
@nl
type
label
Does the dose matter?
@ast
Does the dose matter?
@en
Does the dose matter?
@nl
prefLabel
Does the dose matter?
@ast
Does the dose matter?
@en
Does the dose matter?
@nl
P356
P1476
Does the dose matter?
@en
P2093
P304
P356
10.1086/321854
P407
P478
33 Suppl 3
P577
2001-09-01T00:00:00Z